Search Results

Jennifer Vaz, MD received her medical degree from the Medical College of Virginia before completing a residency in gynecology and obstetrics at Inova Fairfax Hospital. She completed a gynecologic oncology fellowship at the Medical College of Georgia. Following her medical training, Dr. Vaz served as both a gynecologic oncologist and assistant professor of obstetrics and…

A Randomized Open-Label Phase 2/3 Study of Datopotamab-Deruxtecan (Dato-DXd) plus Carboplatin or Cisplatin versus Gemcitabine plus Carboplatin or Cisplatin in Participants with Locally Advanced or Metastatic Urothelial Carcinoma (la/mUC) who Progressed during or After Enfortumab Vedotin (EV) plus Pembrolizumab Combination Treatment – DS1062-328 MOA: Dato-DXD is an ADC that comprises a recombinant humanized anti-TROP2 IgG1…

Mark G. Goldstein, MD, FACP is Board Certified in medical oncology and hematology.  Dr. Goldstein earned a B.S. in genetics at the University of Georgia, then his medical degree from St. George’s University.  He completed his residency at the University of Connecticut with two Commendations for Excellence in Patient Care, followed by a fellowship in…

A Phase 3 Randomized Double-blind Study of Adjuvant Pembrolizumab With or Without V940 in Participants With Resectable Stage II to IIIB (N2) NSCLC not Achieving pCR After Receiving Neoadjuvant Pembrolizumab With Platinum-based Doublet Chemotherapy (INTerpath-009) (V940-009) MOA: V940 is a lipid encapsulated mRNA based Individualized Neoantigen Therapy (INT) encoding neoantigens to induce specific T cells…

D702AC00001: A Randomized, Phase III Study of Rilvegostomig in Combination with Fluoropyrimidine and Trastuzumab Deruxtecan versus Trastuzumab, Chemotherapy, and Pembrolizumab for the First line Treatment of HER2-positive Gastric Cancer. (ARTEMIDE-Gastric01) MOA: Rilvegostomig is a bispecific antibody with an engineered triple-mutant Fc domain targeting PD-1 and TIGIT. Key Eligibility Criteria: Previously untreated, unresectable, locally advanced or…

Next-generation sequencing (NGS) results, treatment flexibility, and patient age must be carefully weighed to determine whether irinotecan liposome (Onivyde) plus oxaliplatin, 5-fluorouracil (5-FU), and leucovorin (NALIRIFOX) is an appropriate first-line treatment for patients with metastatic pancreatic cancer, according to Dong Kim, MD. The regimen received FDA approval for this population in February 2024.1 “One of the…